ProShare Advisors
KROS icon

ProShare Advisors’s Keros Therapeutics KROS Stock Holding History

ProShare Advisors’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,549
Closed -$167K – 2172
2024
Q4 		$167K Buy
10,549
+2,764
+36% +$144K ﹤0.01% 1938
2024
Q3 		$452K Buy
7,785
+2,118
+37% +$105K ﹤0.01% 1193
2024
Q2 		$259K Sell
5,667
-1,469
-21% -$78.9K ﹤0.01% 1391
2024
Q1 		$472K Buy
7,136
+1,496
+27% +$88.7K ﹤0.01% 1124
2023
Q4 		$224K Buy
+5,640
New +$177K ﹤0.01% 1576
2023
Q1 		– Sell
-4,753
Closed -$228K – 1857
2022
Q4 		$228K Buy
+4,753
New +$222K ﹤0.01% 1403
2022
Q2 		– Sell
-5,349
Closed -$291K – 1968
2022
Q1 		$291K Sell
5,349
-1,353
-20% -$69.5K ﹤0.01% 1649
2021
Q4 		$392K Sell
6,702
-284
-4% -$14.2K ﹤0.01% 1622
2021
Q3 		$276K Sell
6,986
-1,248
-15% -$44.4K ﹤0.01% 1607
2021
Q2 		$350K Buy
8,234
+1,479
+22% +$80.1K ﹤0.01% 1786
2021
Q1 		$416K Buy
6,755
+293
+5% +$18.6K ﹤0.01% 1571
2020
Q4 		$456K Buy
+6,462
New +$407K ﹤0.01% 1325

Other funds holding KROS

Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

ProShare Advisors's KROS Position: Q1 2025 in Review

ProShare Advisors sold out of Keros Therapeutics (KROS) in Q1 2025, closing a stake of 10,549 shares — an estimated $167K sold.

ProShare Advisors first reported a position in KROS in Q4 2020 and held it in 12 quarters. The position peaked at $472K in Q1 2024. 156 funds tracked by Wall St. Rank hold KROS as of Q1 2025.

  • ProShare Advisors reported no remaining Keros Therapeutics position as of Q1 2025 after selling out during the quarter.
  • ProShare Advisors sold 10,549 Keros Therapeutics shares in Q1 2025, an estimated $167K.
  • ProShare Advisors first reported a position in Keros Therapeutics in Q4 2020 and held it in 12 quarters.
  • ProShare Advisors's Keros Therapeutics position peaked at $472K in Q1 2024.
  • 156 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2025.

Based on ProShare Advisors's 13F filing for Q1 2025, filed 8 May 2025.